The U.S. Congress implements a new law requiring drug manufacturers to disclose biologic patent settlement agreements to antitrust Authorities (Patient Right to Know Drug Prices Act)

New Law Requires Disclosure of Biologic Patent Settlement Agreements to Antitrust Authorities* Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies agreements between biologic and biosimilar companies that relate to the manufacture, marketing, or sale

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Jones Day (Washington DC)
  • Jones Day (Washington DC)
  • Jones Day (Washington DC)
  • Jones Day (Washington DC)

Quotation

Jonathan Berman, Rosanna McCalips, Julia McEvoy, Larissa Bergin, The U.S. Congress implements a new law requiring drug manufacturers to disclose biologic patent settlement agreements to antitrust Authorities (Patient Right to Know Drug Prices Act), 10 October 2018, e-Competitions Bulletin October 2018, Art. N° 90020

Visites 37

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues